<DOC>
	<DOCNO>NCT02526277</DOCNO>
	<brief_summary>The purpose study ass whether MMF07 Foot Massager and/ heat therapy may improve symptom restless legs syndrome ( RLS ) . It also assess effect MMF07 Foot Massager and/ heat quality life sleep people affect RLS . Participants randomly assign one four treatment group ; 1 . MMF07 Foot Massager device 2 . Heat therapy 3 . Heat therapy MMF07 Foot Massage device 4 . Neither heat MMF07 Foot Massager device ( treatment group )</brief_summary>
	<brief_title>A Study Use MMF07 Foot Massager Heat Therapy Treatments Restless Leg Syndrome</brief_title>
	<detailed_description>Few clinical trial look non-pharmacological , non-invasive treatment restless legs syndrome , despite report massage , baths vibration alleviate RLS symptom . We would like ass whether MMF007 Foot Massager device and/or heat therapy associate improved severity RLS symptom . For study investigator enroll 40 participant diagnose restless legs syndrome , follow course four week ask complete two person study visit . In study investigator compare use MMF007 Foot Massager device and/ heat therapy non treatment group ass symptom RLS improve .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>1 . Subjects 1875 year old diagnose RLS accord diagnostic criterion International Restless Legs Syndrome Study Group ( 11 ) 2 . Subjects bothersome RLS symptom , despite best medical therapy 3 . Subjects stable RLS medication least 4 week prior enrollment 4 . All subject must vision proficient English compliance test survey 5 . All woman childbearing age must use acceptable form birth control , include abstinence , intrauterine device ( IUD ) intrauterine system place least 3 month prior screen , subject partner use barrier method ( e.g. , condom , diaphragm , cervical cap ) spermicide screen study completion ; partner document vasectomy &gt; 6 month prior Baseline , Stable hormonal contraception ( approved oral , transdermal , depot regimen ) least 3 month prior screen 1 . RLS secondary associate end stage renal disease , iron deficiency pregnancy 2 . Concomitant sleep disorder 3 . Any condition ( primary indication ) , opinion investigator might contribute difficulty comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RLS</keyword>
</DOC>